Dehydroepiandrosterone alters phospholipid profiles in Zucker rat muscle tissue.
Insulin-resistant muscle tissue contains low proportions of arachidonic acid (AA), and increased proportions of muscle AA correlate with improved insulin sensitivity. Dehydroepiandrosterone (DHEA) and AA, like the thiazolidinedione drugs that decrease insulin resistance (IR), are peroxisome proliferators. Long-chain fatty acids (FA) have been named the "one true" endogenous ligand for activating the peroxisome proliferator-activator receptor (PPAR), and DHEA has been named a "good candidate" as a naturally occurring indirect activator of PPAR. This study was conducted to determine DHEA's effects on lipid profiles of skeletal and cardiac muscle in lean and obese Zucker rats (ZR), a model of IR, type 2 diabetes mellitus, and obesity. We hypothesize that DHEA may alter long-chain FA profiles in muscle tissue of obese rats such that they more closely resemble that of the lean. In our experiments, we employed a DHEA and a pair-fed (PF) group (n = 6) for 12 lean and 12 obese ZR. For 30 d, the diet of the two DHEA groups was supplemented with 0.6% DHEA; PF groups were given the average daily calories consumed by their corresponding treatment group. Hearts and gastrocnemius muscles were assayed for phospholipid (PL), free FA, and triglyceride (TG) FA profiles. The proportion of PL AA was significantly greater in both muscle types of lean compared to obese rats. Hearts from both DHEA groups had greater PL proportions of AA and less oleic (18:1) acid than their PF controls. Likewise, 18:1 proportions were significantly lower in the gastrocnemius; however, AA proportions were not significantly different. Similar phenotypic profile differences were observed in the TG fraction of both muscle types. There were no DHEA-related TG FA profile alterations.
Abadie
J M
JM
Department of Pathology, Louisiana State University Medical Center, New Orleans 70112, USA. judeabadie@medscape.com
Malcom
G T
GT
Porter
J R
JR
Svec
F
F
D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D003687:Dehydroepiandrosterone / Q000494:pharmacology*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism; D006321:Heart / Q000187:drug effects*; D007333:Insulin Resistance; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism*; D009765:Obesity / Q000188:drug therapy / Q000378:metabolism; D019301:Oleic Acid / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism*; D051381:Rats; D011924:Rats, Zucker; D014280:Triglycerides / Q000378:metabolism
D005227:Fatty Acids; D010743:Phospholipids; D014280:Triglycerides; D016718:Arachidonic Acid; D019301:Oleic Acid; D003687:Dehydroepiandrosterone